(VIANEWS) – Shares of Xenetic Biosciences (NASDAQ: XBIO) dropped by a staggering 15.06% in 5 sessions from $0.52 at -15.06, to $0.44 at 23:24 EST on Tuesday, following the last session’s upward trend. NASDAQ is sliding 1.98% to $11,799.16, after two successive sessions in a row of losses.
Xenetic Biosciences’s last close was $0.44, 61.06% below its 52-week high of $1.13.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-0.4.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.9%.
Volatility
Xenetic Biosciences’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.23%, a positive 0.62%, and a positive 4.76%.
Xenetic Biosciences’s highest amplitude of average volatility was 4.46% (last week), 4.28% (last month), and 4.76% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth grew by 46.4%, now sitting on 1.71M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Xenetic Biosciences’s stock is considered to be overbought (>=80).
More news about Xenetic Biosciences (XBIO).
